Transmission Dynamics of Carbapenemase Genes in Carbapenem-Resistant Enterobacter cloacae: Insights from Guangdong, China (2022–2024)

Study Background and Research Question

Carbapenem-resistant Enterobacteriaceae (CRE) are a major global health concern due to their capacity for multidrug resistance and limited treatment options. Among them, Enterobacter cloacae complex has emerged as a significant contributor to nosocomial infections, particularly in respiratory medicine. The COVID-19 pandemic has further exacerbated challenges, with increased antibiotic use and complex co-infections promoting the emergence and spread of drug-resistant bacteria. Despite the growing prevalence of carbapenem-resistant E. cloacae (CREC), detailed studies exploring the genetic basis, epidemiological patterns, and transmission dynamics of resistance elements, especially carbapenemase-encoding genes (CEGs), have remained scarce. The central research question addressed by Chen et al. (2025) is: What are the molecular characteristics, distribution, and transmission dynamics of CEGs in CREC isolates from major teaching hospitals in Guangdong Province during the pandemic period?

Key Innovation from the Reference Study

This study presents a comprehensive molecular epidemiological analysis of 54 CREC isolates collected prospectively from eight teaching hospitals in Guangdong Province between December 2022 and June 2024. By combining plasmid elimination, PCR, conjugation experiments, and genotyping, the authors delineate the localization, diversity, and transferability of key carbapenemase genes—most notably blaNDM-1. The innovative aspect lies in the systematic mapping of CEGs at both chromosomal and plasmid levels, coupled with robust horizontal transfer studies during a period marked by heightened antibiotic pressure due to COVID-19. This dual approach provides critical insights into how high-risk resistance determinants propagate within and between clinical settings.

Methods and Experimental Design Insights

The investigators applied a multi-tiered methodology to dissect the genetic and epidemiological landscape of CREC resistance:

• Sample Collection: 54 non-duplicate CREC isolates were obtained from eight tertiary hospitals, covering diverse departments and specimen types, with a notable emphasis on respiratory samples.
• Genetic Characterization: Plasmid elimination using variable temperature Sodium Dodecyl Sulfate (SDS) treatment and subsequent PCR enabled determination of CEG presence and their chromosomal/plasmid localization.
• Resistance Profiling: Broth microdilution assays assessed susceptibility to key antimicrobials, including imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin.
• Gene Transfer Studies: Plasmid conjugation experiments and PCR detection quantified the horizontal transfer efficiency of CEGs among isolates.
• Molecular Typing: ERIC-PCR and NTSYS software established clonal relationships and genotype distributions across the cohort.
• Mobile Genetic Element Mapping: PCR-based screening identified six classes of insertion sequences and transposons, with a focus on ISEcp1 as a driver of mobility.

Core Findings and Why They Matter

The reference study provides several pivotal findings:

• High Prevalence of CEGs: 85.19% (46/54) of CREC isolates harbored carbapenemase genes, overwhelmingly dominated by blaNDM-1. Of note, 33.33% carried blaNDM-1 on both chromosomes and plasmids, while 46.30% had it solely on plasmids.
• Diverse Gene Combinations: A minority carried blaIMP (3.70%) or both blaNDM-1 and blaKPC-2 (1.85%) on plasmids, highlighting the genetic complexity and potential for co-resistance.
• Resistance Phenotypes: CEG-positive isolates demonstrated significantly higher resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin compared to CEG-negative strains. This underscores the challenge in treating infections such as bacterial pneumonia or bronchitis caused by these organisms.
• Efficient Horizontal Transfer: Plasmid conjugation experiments achieved a 95.65% success rate for CEG transfer, with blaNDM-1 and blaIMP showing high mobility. This rapid dissemination capability raises concerns for healthcare-associated outbreaks and highlights the need for vigilant antimicrobial stewardship and infection control.
• Mobile Genetic Elements: Six types of mobile elements were detected, with ISEcp1 present in 87.04% of isolates. The presence of multiple mobile elements (up to four per isolate) facilitates complex genetic rearrangements and further accelerates resistance spread.
• Clonal Diversity and Epidemiology: Genotyping revealed 17 distinct CREC types, with type E and G most prevalent across multiple hospitals and departments, including respiratory medicine. Elderly male patients and sputum specimens had the highest rates of CEG detection, indicating susceptible populations and potential reservoirs.

Together, these results clarify the molecular drivers behind the rapid emergence and spread of carbapenem-resistant, multidrug-resistant Gram-negative infections in clinical settings—particularly within the context of respiratory disease management. The findings build a foundation for targeted surveillance and inform the design of research models to study Gram-negative bacterial infection and resistance mechanisms.

Comparison with Existing Internal Articles

Several recent reviews and protocol guides have addressed the translational significance of third-generation cephalosporins—especially ceftazidime—in the context of multidrug-resistant Gram-negative bacteria. For instance, the article “Ceftazidime in Translational Research: Mechanisms and Strategy” synthesizes genomic surveillance data with practical guidance for infection modeling, emphasizing the importance of β-lactamase resistance and the critical role of ceftazidime in experimental workflows. Similarly, “Ceftazidime in Translational Research: Navigating Resistance” provides a strategic perspective on using ceftazidime for Gram-negative infection models, underscoring the relevance of resistance gene dynamics. These articles echo the reference study’s findings: the prevalence of plasmid-borne carbapenemase genes like blaNDM-1 fundamentally challenges the efficacy of traditional antibiotics and necessitates robust experimental controls and surveillance in translational research. Furthermore, the in-depth workflow advice in “Ceftazidime in Gram-Negative Infection Research: Protocols & Pitfalls” aligns with the need for careful protocol design in the face of rapidly spreading resistance determinants.

Limitations and Transferability

While the study by Chen et al. provides a detailed and region-specific snapshot of CEG epidemiology, several limitations merit consideration. First, the cohort size is modest, and findings may not generalize beyond the sampled hospitals or beyond Guangdong Province. The focus on teaching hospitals may also introduce selection bias toward more severe or refractory cases. Furthermore, the observational period coincides with the COVID-19 pandemic, which may have altered antibiotic usage and infection dynamics compared to baseline years. Nevertheless, the robust molecular and epidemiological framework is transferable to other settings, especially for researchers modeling Gram-negative resistance, infection transmission, or evaluating interventions for the treatment of bacterial pneumonia and bronchitis.

Protocol Parameters

• Isolate selection: Collect non-duplicate CREC strains from diverse clinical sources, with an emphasis on respiratory specimens for relevance to pneumonia/bronchitis models.
• Genetic analysis: Use variable temperature SDS plasmid elimination followed by PCR to determine CEG presence and localization.
• Antibiotic susceptibility testing: Employ broth microdilution for compounds such as imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin.
• Conjugation protocols: Perform filter mating or liquid mating assays to assess plasmid transfer efficiency, followed by PCR confirmation of CEG acquisition in recipient strains.
• Genotyping: ERIC-PCR combined with cluster analysis (e.g., NTSYS) to map clonal lineages and outbreak potential.
• Mobile element screening: PCR for insertion sequences such as ISEcp1 to identify genetic mobility factors relevant to resistance dissemination.

Research Support Resources

For researchers seeking to model or counteract multidrug-resistant Gram-negative infections, particularly those involving Pseudomonas aeruginosa or Enterobacteriaceae, third-generation cephalosporins remain key experimental tools. Ceftazidime (SKU B3539) from APExBIO offers a β-lactamase-resistant profile and is widely used for both mechanistic studies and preclinical infection models. Its robust activity against Gram-negative bacteria and clinical relevance in the treatment of bacterial pneumonia and bronchitis make it suitable for validating resistance phenotypes and experimental interventions. Researchers should refer to the product documentation for storage, solubility, and protocol recommendations to ensure experimental reproducibility and reliability.